Personalized Cognitive Therapy via Endophenotype Biomarker Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating cognitive dysfunction are ineffective due to a one-size-fits-all approach, failing to account for individual biological variations, leading to inconsistent results and lack of personalized treatment strategies.
Innovation Solution
A method involving the identification of endophenotypes such as pro-inflammatory, metabolic, neurotrophic, and depressive endophenotypes through biomarker analysis to tailor therapy selection for improved cognition or prevention of cognitive loss, using anti-inflammatory, anti-diabetic, neurotrophic factor, and antidepressant therapies based on specific endophenotypic profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a one-size-fits-all approach is used for treating cognitive dysfunction, then treatment simplicity is maintained, but treatment effectiveness deteriorates due to failure to account for individual biological variations
Solution Approach 1:
The patent segments patients into distinct endophenotypic subgroups (pro-inflammatory, metabolic, neurotrophic, depressive) based on biomarker profiles. This segmentation allows tailored therapy selection for each subgroup, resolving the contradiction by making treatment effective through personalization while managing complexity through systematic classification.
Solution Approach 2:
The patent changes the parameter of treatment selection from a uniform approach to a personalized approach based on measured biomarker parameters. By measuring specific biomarkers (inflammatory markers, metabolic markers, neurotrophic factors, depressive symptoms) and using these parameters to guide therapy selection, the patent achieves both effectiveness and manageable complexity.
2Reliability
If personalized treatment strategies are implemented through biomarker analysis, then treatment effectiveness improves, but diagnostic complexity and cost increase
Solution Approach 1:
The patent applies a universal biomarker analysis framework that can identify multiple endophenotypes (pro-inflammatory, metabolic, neurotrophic, depressive) using a comprehensive set of biomarkers. This multi-functional approach allows a single diagnostic process to serve multiple classification purposes, improving treatment response prediction while managing diagnostic complexity through an integrated system.
Solution Approach 2:
The patent uses biomarker profiles as intermediaries between patient biology and treatment selection. Instead of directly observing complex biological variations, the patent measures specific biomarkers that serve as measurable proxies, making the diagnostic process more manageable while still capturing individual biological differences for personalized treatment.
3Object-affected harmful factors
If therapy selection is based on endophenotypic profiling, then adverse effects are reduced through appropriate therapy matching, but treatment planning complexity increases
Solution Approach 1:
The patent applies local quality by matching specific therapies to specific endophenotypic subgroups. Each subgroup (pro-inflammatory, metabolic, neurotrophic, depressive) receives a tailored therapy approach appropriate to its biological characteristics. This localized matching reduces adverse effects by avoiding inappropriate treatments while managing planning complexity through clear subgroup-specific guidelines.
Data Source
AI summary
The present invention includes methods for selecting a therapy for improved cognition as well as prevention of cognitive loss/dysfunction using one or more endophenotypes comprising: obtaining a sample from a subject; measuring biomarkers that differentiate between an inflammatory, a metabolic, a neurotrophic, and a depressive endophenotype; and selecting a course of treatment for the subject based on whether the subject is scored as having a high or a low endophenotype for one or more of the inflammatory, a metabolic, a neurotrophic, and a depressive endophenotypes.